Immunovant, Inc. IMVT
33.21 USD -0.07 (-0.21%)
Regular-session close
33.21 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
32.45 Day range 33.82
21.86 52-week range 45.42
- YTD
- +30.65%
- 1 year
- +36.67%
News
benzinga.com David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes DME Capital Management reveals its new third-quarter stock picks. Here's what David Einhorn has been buying.
zacks.com Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the…
seekingalpha.com Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in…
zacks.com Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.
benzinga.com Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
